Citation-backed change ledger

What changed recently?

Follow records added to PeptideScanner separately from revised profiles, corrections, and retractions. Every event keeps its date, before-and-after state, preserved version links, and supporting public sources.

5446Ledger events
5308Record additions
138Version changes
November 17, 2026Latest change date

Source-published notices

Research integrity connected to synthesis

Open the complete integrity record →

These are Crossref-attributed publisher or Retraction Watch notices, not PeptideScanner corrections. The source-event dates and PeptideScanner review date remain separate.

Preserved version history

Profile and record changes

Trust-critical corrections →

These are the latest routine updates, status changes, corrections, and retractions. Before-and-after fields are derived from adjacent preserved public versions.

Profile updated

GHRP-2 profile

We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported in the cited sources, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

Cited source records

Before
fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
After
fda-ghrp-2-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-503a-nominations-2026-05-14, journal-pmid-17609397, journal-pmid-16861611

Claim citations

Before
name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
After
name: fda-ghrp-2-identity, fda-bulk-peptide-risks; aliases: fda-ghrp-2-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ghrp-2-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-16861611, journal-pmid-17609397, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
Profile updated

Insulin glargine-aldy profile

We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
After
Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.

Cited source records

Before
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026
After
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026, fda-lantus-label-2023

Claim citations

Before
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026
After
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-lantus-label-2023, fda-langlara-approval-2026
Profile updated

LL-37 profile

We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Profile summary

Before
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, that FDA lists among compounding substances that may present significant safety risks.
After
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.

Evidence note

Before
FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

Related names

Before
Cathelicidin LL-37, Ropocamptide
After
Cathelicidin LL-37, Ropocamptide, LL37

Cited source records

Before
fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
After
fda-ll-37-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-25041740, journal-pmid-34687253, journal-pmid-37480520, ctg-observation-nct02225366-2021-12-09-d146b413ecf5

Claim citations

Before
name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
After
name: fda-ll-37-identity, fda-bulk-peptide-risks; aliases: fda-ll-37-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-ll-37-identity, fda-bulk-peptide-risks, journal-pmid-34687253; evidenceNote: journal-pmid-34687253, journal-pmid-25041740, journal-pmid-37480520, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
Profile updated

Melanotan II profile

We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
FDA cites published case reports of melanoma, brain swelling, stimulant-like toxicity and priapism in people who used Melanotan II. No FDA approval is reported in the cited sources, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

Cited source records

Before
fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
After
fda-melanotan-ii-identity, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, fda-pcac-503a-meeting-2027, journal-pmid-8637402, journal-pmid-11018622

Claim citations

Before
name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
After
name: fda-melanotan-ii-identity, fda-bulk-peptide-risks; aliases: fda-melanotan-ii-identity; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-melanotan-ii-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-8637402, journal-pmid-11018622, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
Profile updated

Octreotide profile

We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.
After
The generic label cited here describes no trials of its own and states that its trials did not show improvement in symptoms or tumor size. Randomized trials of two other octreotide products, Sandostatin LAR and Mycapssa, are described in their own FDA labels.

Cited source records

Before
dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531
After
dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024

Claim citations

Before
name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, journal-pmid-2229278, journal-pmid-34953531
After
name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-sandostatin-lar-label-2024, fda-mycapssa-label-2024, journal-pmid-2229278, journal-pmid-34953531
Profile updated

Petrelintide profile

We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.
After
A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.

Cited source records

Before
ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d
After
ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d, journal-pmid-42810355, ctg-observation-nct07843498-2026-11-05-9b532d149aaf, ctg-observation-nct07076030-2026-01-28-68a10be352b4

Claim citations

Before
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42810355, journal-pmid-42017294, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
Profile updated

Selank profile

We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
No human study is cited in the reviewed sources; the published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

Cited source records

Before
fda-selank-identity, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
After
fda-selank-identity, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026, journal-pmid-26356395

Claim citations

Before
name: fda-selank-identity, fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-selank-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
After
name: fda-selank-identity, fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-selank-identity, fda-bulk-peptide-risks; evidenceNote: journal-pmid-26356395, journal-pmid-28280289, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
Record updated

ClinicalTrials.gov record NCT04775082

ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.

Cited source date

Before
2026-07-09
After
2026-11-16

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
ctg-observation-nct04775082-2026-07-09-b565460c570f
After
ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

Headline citations

Before
ctg-observation-nct04775082-2026-07-09-b565460c570f
After
ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

Summary citations

Before
ctg-observation-nct04775082-2026-07-09-b565460c570f
After
ctg-observation-nct04775082-2026-07-09-b565460c570f-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2]

Source snapshot commitment

Before
24552ee10aefc7c1245f029d4f1a81e678fa6746e5732b6ca15443b96475d446
After
5a2567b8b21c49bf22892d25aa2445244756f58c089059fc0f1d2d68b2007b4d
Record updated

ClinicalTrials.gov record NCT05278208

ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
After
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

Cited source date

Before
2026-07-20
After
2026-11-16

Cited source records

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Headline citations

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Summary citations

Before
ctg-observation-nct05278208-2026-07-20-294c4af79959
After
ctg-observation-nct05278208-2026-07-20-294c4af79959-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2]

Source snapshot commitment

Before
27842e169ac0417a0d1e79de9ecf095381201b52a0342053ddcf98a7ea8d7793
After
caf11e90bc5b4e47237f7e29c972eafdab923d3b708553f0c1c65a7b25eae129
Record updated

ClinicalTrials.gov record NCT05669664

ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
After
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.

Cited source date

Before
2026-06-17
After
2026-11-16

Source observed date

Before
2026-07-30
After
2026-11-16

Cited source records

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Headline citations

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Summary citations

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2]

Source snapshot commitment

Before
89e592b23c98d73045c9944adc28bbf5c628a3ebc7d2a85512423412fd1ca5c5
After
b3a5ff90419c4c0a50b967a4dcdb2433c975a8120c2f378701ac9c463645c350
Record updated

ClinicalTrials.gov record NCT06015893

ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.

Cited source date

Before
2026-08-03
After
2026-11-16

Source observed date

Before
2026-08-13
After
2026-11-16

Cited source records

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Headline citations

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Summary citations

Before
ctg-observation-nct06015893-2026-08-03-32ebc1c71794
After
ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]

Source snapshot commitment

Before
a4aeea2f9b0f59d39a847b4a9aeb5803154bc2def132f9465486d71eee198e5c
After
89b6fa98e2a99b1140238cec416d1f9a55fb79d619a93bb0413e7922c3bc223a
Record updated

ClinicalTrials.gov record NCT07220759

ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.

Cited source date

Before
2026-08-03
After
2026-11-16

Source observed date

Before
2026-08-13
After
2026-11-16

Cited source records

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Headline citations

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Summary citations

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]

Source snapshot commitment

Before
25fdc0e1abb2c8ef471c57c54351ee7c4138fb59866fb3a21639ee2b2a876300
After
9223ed410ea30b6c045445fd7c2ca6ef3168ef01beef2c6fcaf1fa4c392ff10e
Record updated

ClinicalTrials.gov record NCT07843472

ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.

Cited source date

Before
2026-10-07
After
2026-11-16

Source observed date

Before
2026-11-14
After
2026-11-16

Cited source records

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Headline citations

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Summary citations

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2]

Source snapshot commitment

Before
7839bde20c43885ca3c0ba78ceb7f2a639b702d6768d2a5fcdcf2a721f0540d4
After
26eb9ec866334a946792b0839f2306bcc8dfd707b971edc13ad9bf3520b3d5db
Record updated

Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome.

PubMed revised the bibliographic metadata of PMID 40484968, with a metadata revision date of 2026-10-14. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
October 14, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2025-06-11
After
2026-10-14

Source observed date

Before
2026-07-30
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
After
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

Headline citations

Before
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
After
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

Summary citations

Before
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99
After
pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2

Attributable context

Before
1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99]
After
1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2]

Source snapshot commitment

Before
9b26f496b85118b02931ab1701b5b96b6376ccd66902857011505ee42468f951
After
3a6a88d99388c6145fbf4989900e2d739ed73e18a04045e4a51ee2b6730394ae
Record updated

Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-17
After
2026-11-01

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Headline citations

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Summary citations

Before
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c
After
pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2

Attributable context

Before
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
After
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]

Source snapshot commitment

Before
eab353679f205fa5faa1c057fdb6bd19f62c13d6b1d4c1142774b7af3956a42d
After
34b907ddc6cec008126f746b3c051e747e49a7b1a5d931a71ddab936a8fe30cd
Record updated

Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice.

PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
October 28, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-26
After
2026-10-28

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
After
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

Headline citations

Before
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
After
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

Summary citations

Before
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38
After
pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2

Attributable context

Before
1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38]
After
1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2]

Source snapshot commitment

Before
2f489fa036a3bef3c01c415fdc534b027a76bb57092086428e59967706b46da0
After
7a40e26c7f83edcd1cf0060e963968f983e37478f69fbcbbcb1b5b2ff40ea51b
Record updated

Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.

PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-04
After
2026-11-04

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
After
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

Headline citations

Before
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
After
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

Summary citations

Before
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583
After
pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2

Attributable context

Before
1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583]
After
1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2]

Source snapshot commitment

Before
4b3bd921a7d46c4b11998a3baec46da86d4c796af65645a749df5d3cebf50f50
After
1905f6b7c204dbbf7f742180be1de6d9b1634888554db65350b42f9cfaa2fa99
Record updated

Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata

Summary

Before
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Cited source date

Before
2026-07-10
After
2026-10-09

Source observed date

Before
2026-08-10
After
2026-11-16

Cited source records

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Headline citations

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Summary citations

Before
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313
After
pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2

Attributable context

Before
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
After
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2] 2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]

Source snapshot commitment

Before
40371d4fc303f9890f165794e7bc1cdff3c5d283a74e058cd08dfec64e487e62
After
049db8537e8e0ed1acbba612a8b6e19e7a2b629ebe72c72ef6a452ac2b240137

Collection activity

Recently added evidence records

Browse the latest 100 additions →

These records entered PeptideScanner most recently. Their separately labeled cited source dates may be much older.

Record added

ClinicalTrials.gov record NCT03606577

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05344469

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 17, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06152575

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07555938

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07715903

PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record added

Drugs@FDA application ANDA090218

The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
April 16, 2015
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA091646

The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
October 3, 2017
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA203857

The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
September 25, 2024
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA206873

The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
September 25, 2024
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA206921

The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
February 12, 2018
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA206936

The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
October 3, 2017
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA208468

The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
May 7, 2025
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA209330

The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
June 11, 2021
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA209422

The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
September 9, 2019
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA209425

The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
March 16, 2020
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA209526

The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
July 20, 2026
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA211185

The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
March 20, 2020
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA213382

The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
February 11, 2026
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA214022

The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
February 11, 2026
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA214741

The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
December 31, 2025
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA217591

The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
November 10, 2025
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA218602

The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
February 26, 2026
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA218929

The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
November 26, 2025
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA219465

The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
October 23, 2025
Evidence lane
Regulatory
Record added

Drugs@FDA application ANDA219604

The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
June 4, 2026
Evidence lane
Regulatory
Record added

Drugs@FDA application BLA021839

The official Drugs@FDA dataset lists original submission 1 for BLA 021839 with status AP dated 2005-08-30, and names mecasermin recombinant among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
August 30, 2005
Evidence lane
Regulatory
Record added

Drugs@FDA application BLA125390

The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
February 24, 2014
Evidence lane
Regulatory
Record added

Drugs@FDA application BLA125431

The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
April 15, 2014
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA018123

The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
September 30, 1982
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA020622

The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
December 20, 1996
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA021883

The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
May 23, 2014
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA202714

The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
July 20, 2012
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA202799

The official Drugs@FDA dataset lists original submission 1 for NDA 202799 with status AP dated 2012-03-27, and names peginesatide acetate among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
March 27, 2012
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA208547

The official Drugs@FDA dataset lists original submission 1 for NDA 208547 with status AP dated 2016-06-01, and names gallium dotatate ga-68 among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
June 1, 2016
Evidence lane
Regulatory
Record added

Drugs@FDA application NDA220934

The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.

PeptideScanner change date
November 17, 2026
Cited source date
April 1, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2011-27327

The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

PeptideScanner change date
November 17, 2026
Cited source date
October 24, 2011
Evidence lane
Regulatory